GAM
TEVA icon

Goldentree Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Goldentree Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,179,215
Closed -$18.1M – 37
2025
Q1 		$18.1M Sell
1,179,215
-786,059
-40% -$14M 1.29% 25
2024
Q4 		$43.2M Sell
1,965,274
-339,719
-15% -$6.18M 3.32% 7
2024
Q3 		$41.5M Sell
2,304,993
-180,657
-7% -$3.16M 3.31% 9
2024
Q2 		$40.4M Buy
2,485,650
+427,000
+21% +$6.58M 3.35% 9
2024
Q1 		$29M Sell
2,058,650
-1,816,350
-47% -$22.9M 2.31% 17
2023
Q4 		$40.5M Buy
+3,875,000
New +$36.2M 4.2% 8
2023
Q1 		– Sell
-2,493,348
Closed -$22.7M – 38
2022
Q4 		$22.7M Buy
+2,493,348
New +$21.8M 1.83% 13
2022
Q3 		– Sell
-3,822,965
Closed -$28.7M – 34
2022
Q2 		$28.7M Buy
+3,822,965
New +$33.3M 1.87% 16
2019
Q2 		– Sell
-1,012,580
Closed -$15.9M – 27
2019
Q1 		$15.9M Sell
1,012,580
-839,055
-45% -$14.8M 1.71% 16
2018
Q4 		$28.6M Buy
+1,851,635
New +$38M 4.5% 7

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Goldentree Asset Management's TEVA Position: Q2 2025 in Review

Goldentree Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 1,179,215 shares — an estimated $18.1M sold.

Goldentree Asset Management first reported a position in TEVA in Q4 2018 and held it in 10 quarters. The position peaked at $43.2M in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Goldentree Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Goldentree Asset Management sold 1,179,215 Teva Pharmaceuticals shares in Q2 2025, an estimated $18.1M.
  • Goldentree Asset Management first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 10 quarters.
  • Goldentree Asset Management's Teva Pharmaceuticals position peaked at $43.2M in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Goldentree Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.